A Phase 4 interventional study of Ferric Carboxymaltose (FCM) and Sodium Chloride (NaCl) 0.9 % in Pulmonary Hypertension and Iron Deficiency, sponsored by Ziekenhuis Oost-Limburg. Recruiting at 7 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Ziekenhuis Oost-Limburg · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Hypertension, Pulmonary with a site in Belgium — 11 open to participants now, 17 under way, 5 of them phase 3. Hypertension, Pulmonary · Belgium.
Among the 70 studies in Hypertension, Pulmonary with a site in Belgium, this one is the 16th largest by planned enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 4, reaches primary completion later than 13 of the 16 other live ones, and was the 70th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →11 of the 70 studies in Hypertension, Pulmonary with a site in Belgium are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Belgium, United States, Australia and 7 more countries
Ages 18+
Liquidia Technologies, Inc. · Sites in Belgium, United States, Australia and 9 more countries
Ages 18–80
Insmed Incorporated · Sites in Belgium, United States, Argentina and 27 more countries
Ages 18+
KU Leuven · Sites in Belgium
Ages 18+
Actelion · Sites in Belgium, Belarus, Bulgaria and 10 more countries
Ages 2+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 32 · Phase 4 2
First in 2000; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 306 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 185 across the 57 interventional studies, 500 across the 12 observational. Of the 51 that completed or were terminated, 27 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 70 have an industry lead sponsor. The 10 most frequent:
Ziekenhuis Oost-Limburg is the lead sponsor of 69 studies on the registry; 16 are open to participants now.
Ziekenhuis Oost-Limburg has 1 study filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypertension, Pulmonary with a site in Belgium that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT06616974Tectonic TherapeuticA Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | 2026-11-24 |
| NCT01347216Technische Universität DresdenCOMPERA / COMPERA-KIDS | 2026-12-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 70 studies in Hypertension, Pulmonary with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pulmonary hypertension (PH) is a condition characterized by elevated blood pressure in the pulmonary arteries. This leads to symptoms such as shortness of breath and a significantly reduced exercise capacity, resulting in a very poor quality of life. Currently, treatment options for PH are limited.
More than 60% of patients with PH develop iron deficiency. Studies have shown that this deficiency is associated with more severe symptoms, reduced exercise capacity, and even lower quality of life. Oral iron supplements are often ineffective in these patients due to impaired absorption in the intestines, caused by chronic low-grade inflammation-a common feature in PH.
Intravenous iron administration can rapidly correct the deficiency, but it remains unclear whether this also leads to clinical improvements such as enhanced exercise capacity, reduced shortness of breath, and improved quality of life. Moreover, the cost-effectiveness of this treatment is still unknown. The IRON-PH study aims to answer these questions.
As part of the IRON-PH study, 306 patients with pulmonary hypertension will be enrolled. Each patient will be randomized to receive either intravenous iron (ferric carboxymaltose) or intravenous placebo (NaCl 0.9%).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PH defined by echocardiography and/or right heart catheterization (RHC) according to the following WHO groups:
Group 1 PH:
Group 2 PH and baseline > 50% on imaging modality within last 6 months before randomization and on stable doses of loop diuretics and HFpEF therapies for 4 weeks. Group 2 PH can be included based on echocardiography or RHC.:
Echocardiography (\<6mo before randomization):
RHC (\<6mo before randomization)
Group 4 PH:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ferric Carboxymaltose (FCM)
Drug: Sodium Chloride (NaCl) 0.9 %
Ferric Carboxymaltose (FCM), dosing and administration according to SmPC guidelines
Placebo, dosing and administration according to SmPC guidelines
Change in 6MWD
Change in 6-minute walking distance (6MWD) from baseline to 24 week follow-up
Time frame: From baseline to 24 week follow-up
Change in MLHFQ
Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) score from baseline to 24 week follow-up. Total Score: Sum of all 21 items (0-105) Higher Score = Worse QoL: A higher number indicates a greater negative impact from heart failure Lower Score = Better QoL: A lower score suggests less limitation
Time frame: Baseline to 24 week follow-up
Change in EQ5D5L
Change in EuroQol 5 dimensions - 5 levels questionnaire score from baseline to 24 week follow-up EQ-5D-5L combiines responses from five health dimensions, each with five severity levels to create a 5-digit health state code, then applying country-specific "value sets" (valuation matrices) to convert this code into a single Index Score (Utility Score), ranging from \<0 (worst) to 1 (best health), plus a separate EQ-VAS score (0-100) for overall self-rated health. Dimensions: Mobility, self-care, usual activities, pain/discomfort, anxiey/depression Levels: 1 no problem, 2 slight problems, 3 moderate problems, 4 severe problems, 5 unable to/extreme problems Example of 5-digit state code: 12345 indicates no problems with mobility, slight problems with self-care, moderate problems with usual activities, severe pain/discomfort and extreme anxiety/depression
Time frame: Baseline to 24 week follow-up
Change in FSS
Change in Fatigue Severity Scale (FSS) score from baseline to 24 weeks Total score: sum of all scores (ranging between 9 - 63) Higher Scores = More Fatigue Lower Scores = Less Fatigue
Time frame: Baseline to 24 week follow-up
Developing composite clinical worsening event
The hazard ratio between treatment arms in developing the composite clinical worsening event in the overall trial population
Time frame: From first patient Day 1 (Baseline) to study completion, an average of 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jul 2028, 30 months after the start.
Of 23 phase 4 interventional studies under Hypertension, Pulmonary, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 54. This study's planned 30 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose
Ziekenhuis Oost-Limburg